

# Phospho-BAP1 (Ser592) Antibody



**Orders:** 877-616-CELL (2355)  
orders@cellsignal.com

**Support:** 877-678-TECH (8324)

**Web:** info@cellsignal.com  
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

**For Research Use Only. Not for Use in Diagnostic Procedures.**

<b>Applications:</b> W, IP	<b>Reactivity:</b> H	<b>Sensitivity:</b> Endogenous	<b>MW (kDa):</b> 95	<b>Source/Isotype:</b> Rabbit	<b>UniProt ID:</b> #Q92560	<b>Entrez-Gene Id:</b> 8314
-------------------------------	-------------------------	-----------------------------------	------------------------	----------------------------------	-------------------------------	--------------------------------

## Product Usage Information

### Application

Western Blotting  
Immunoprecipitation

### Dilution

1:1000  
1:50

## Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at -20°C. Do not aliquot the antibody.

## Specificity/Sensitivity

Phospho-BAP1 (Ser592) Antibody detects endogenous levels of BAP1 only when phosphorylated at Ser592.

## Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Ser592 of human BAP1.

## Background

BAP1 (BRCA1-Associated Protein 1) was originally identified as a BRCA1 associated, nuclear localized ubiquitin hydrolase that suppresses cell growth (1). The protein belongs to the UCH family of deubiquitinases, with a UCH domain in its N-terminal segment and a BRCA1 interaction domain as well as a nuclear localization signal in its C-terminal segment (1). Frequent gene locus rearrangement, deletion and null mutation of BAP1 have been found in lung and breast cancers (1,2). Mutation analysis *in vivo* in cancer cell line survival and in animal tumorigenesis indicate that both the deubiquitinase activity and the nuclear localization signal are required for BAP1 function as a tumor suppressor (3). BAP1 does not have direct deubiquitination activity towards the autoubiquitinated BRCA1/BARD1 E3 complex (4), but its interaction with BARD1 inhibits BRCA1/BARD1 E3 activity by interfering with the complex dimerization process (5). In addition to its interaction with BRCA1/BARD1, BAP1 has also been shown to interact with and deubiquitinate HCF-1, thereby controlling its stability (6). Phosphorylation of Ser592 on BAP1 was identified at Cell Signaling Technology (CST) using PhosphoScan®, CST's LC-MS/MS platform for phosphorylation site discovery (7).

## Background References

1. Jensen, D.E. et al. (1998) *Oncogene* 16, 1097-112.
2. Buchhagen, D.L. et al. (1994) *Int J Cancer* 57, 473-9.
3. Ventii, K.H. et al. (2008) *Cancer Res* 68, 6953-62.
4. Mallery, D.L. et al. (2002) *EMBO J* 21, 6755-62.
5. Nishikawa, H. et al. (2009) *Cancer Res* 69, 111-9.
6. Misaghi, S. et al. (2009) *Mol Cell Biol* 29, 2181-92.
7. Rush, J. et al. (2005) *Nat Biotechnol* 23, 94-101.

## Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

## Western Blot Buffer

**IMPORTANT:** For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

## Applications Key

**W:** Western Blotting **IP:** Immunoprecipitation

## Cross-Reactivity Key

**H:** Human

## Trademarks and Patents

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit [cellsignal.com/trademarks](http://cellsignal.com/trademarks) for more information.

## Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless

separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.